At the core of Tirzepatide’s efficacy lies its ability to emulate the actions of GLP-1 and GIP. These hormones play pivotal roles in regulating appetite and signaling satiety to the brain. Tirzepatide, by mimicking these natural messengers, actively communicates with the body to enhance the feeling of fullness. This, in turn, effectively curbs cravings and reduces the desire to overeat, promoting a sustainable and healthier approach to weight management.
One of the key mechanisms of Tirzepatide is its role in signaling to the brain when the body has had enough sustenance. By suppressing appetite through the activation of GLP-1 and GIP receptors, Tirzepatide supports individuals in making mindful dietary choices, fostering a more controlled and balanced approach to eating.
At Lunamé Medical Aesthetics, we prioritize the safety and well-being of our patients. As part of the comprehensive assessment process, certain laboratory tests are a crucial component to ensure the suitability and efficacy of the treatment. The patient is responsible for obtaining and covering the costs associated with these necessary lab tests. These tests are essential in gauging various health parameters, enabling our medical professionals to tailor the weight loss program to each individual’s unique needs and circumstances.
Tirzepatide works by activating two hormone receptors – GLP-1 and GIP – giving it a potential edge over semaglutide, which only targets the GLP-1 receptor. By influencing two pathways instead of one, tirzepatide may provide greater effects on blood glucose, appetite, and weight loss. Some studies suggest that tirzepatide’s dual action mechanism may make it a more potent medication for weight loss compared to semaglutide. There is evidence that tirzepatide leads to greater reductions in body weight and BMI in clinical trials. However, more head-to-head research is needed to make definitive conclusions.
Yes generally this is a well, safe tolerated treatment. Like any other medications there may be risks and side effects.
Tirzepatide is administered via subcutaneous injections in office.